FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
Portfolio Pulse from Vandana Singh
The FDA has approved Adaptimmune Therapeutics' (NASDAQ:ADAP) Tecelra for treating unresectable or metastatic synovial sarcoma, marking the first engineered cell therapy for solid tumors in the U.S. and the first new therapy for this rare cancer in over a decade. The approval is based on the SPEARHEAD-1 trial results, showing a 43% overall response rate. Adaptimmune plans to establish multiple treatment centers. Additionally, Adaptimmune has entered a collaboration with Galapagos NV (NASDAQ:GLPG) for future TCR T-cell therapies.
August 02, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
FDA approval of Tecelra for synovial sarcoma marks a significant milestone for Adaptimmune Therapeutics, being the first engineered cell therapy for solid tumors in the U.S. The stock is up 7.09% in premarket trading.
The FDA approval is a major regulatory milestone, likely to boost investor confidence and drive the stock price up in the short term. The premarket increase of 7.09% reflects positive market sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Galapagos NV has entered a clinical collaboration with Adaptimmune for future TCR T-cell therapies, including a $100 million initial payment to Adaptimmune. This partnership could enhance Galapagos' pipeline and market position.
The collaboration with Adaptimmune and the significant financial commitment indicate potential growth opportunities for Galapagos, which could positively impact its stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 50